Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | CFB | P00751 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.41 |
| ▸ | PNP | P00491 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721092 | 1.00 | PARP1 (0.52) | PARP1CFBKDM4ESPHK1SPHK2 | |
| SCHEMBL1720371 | 1.00 | PARP1 (0.52) | PARP1CFBKDM4ESPHK1SPHK2 | |
| SCHEMBL1720592 | 0.86 | DDR1 (0.45) | PARP1CFBKDM4ESPHK1SPHK2 | |
| SCHEMBL1720556 | 0.86 | PARP1 (0.43) | PARP1CFBKDM4ESPHK1SPHK2 | |
| SCHEMBL1720740 | 0.86 | PARP1 (0.43) | PARP1CFBKDM4ESPHK1SPHK2 | |
| SCHEMBL1720739 | 0.86 | PARP1 (0.43) | PARP1CFBKDM4ESPHK1SPHK2 | |
| SCHEMBL1719879 | 0.86 | DDR1 (0.45) | PARP1CFBKDM4ESPHK1SPHK2 | |
| SCHEMBL1719877 | 0.86 | DDR1 (0.45) | PARP1CFBKDM4ESPHK1SPHK2 | |
| SCHEMBL1720531 | 0.86 | PARP1 (0.56) | PARP1CFBKDM4ESPHK1SPHK2 | |
| SCHEMBL1720534 | 0.86 | PARP1 (0.56) | PARP1CFBKDM4ESPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | claimed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | claimed |
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | PARP1 1/4885CFB 3353/4885KDM4E 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.